Association of statin therapy on acute ischemic stroke patients with atrial fibrillation: insights from a nationwide cohort study

 Is your competent? doctor ready to embed this in your recovery protocols?

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

Association of statin therapy on acute ischemic stroke patients with atrial fibrillation: insights from a nationwide cohort study

 Hyunsoo Kim 

Seung Hyun Min 

Jae-Myung Kim, 

Kang-Ho Choi, 

Jungkuk Lee, 

Joon-Tae Kim  

Scientific Reports , Article number: ;(2026) We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply. 

Abstract

 Although statins are well-established in improving outcomes after ischemic stroke, their effectiveness in patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) without conventional indications remains uncertain. This study investigates the association between statin therapy and vascular outcomes in patients with AIS and AF without previously diagnosed atherosclerotic cardiovascular disease (ASCVD). This retrospective, nationwide cohort study utilized the Korean National Health Insurance Service database (2011–2023). Patients aged ≥ 20 years with AIS or transient ischemic attack and concurrent AF were included if they underwent neuroimaging, had no prior statin use at admission, and no documented history of ASCVD. Propensity score matching and inverse probability of treatment weighting (IPTW) were used to adjust for potential confounders. The primary outcome was a composite of all-cause death, ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), and myocardial infarction within 1 year. Hazard ratios (HR) were estimated using Cox regression. Subgroup analyses assessed the association of statin dose (high vs. standard), ezetimibe combination therapy, and statin type. A total of 64,190 patients (mean age; 73.76, male 55.3%) were finally analyzed and categorized into statin users (n = 37,033) and non-users (n = 27,157). In the IPTW analysis, statin-user was associated with lower risk for primary vascular outcomes (HR 0.821 [95% CI 0.808–0.835]), mortality (HR 0.746 [0.729–0.763]), ischemic stroke and systemic embolism (HR 0.904 [0.884–0.925]), and ICH (HR 0.725 [0.660–0.796]) compared to non-users. Neither statin dose, statin type, nor ezetimibe combination was significantly associated with differences in the primary outcome. In patients with AIS and AF without previously diagnosed ASCVD, statin therapy was associated with a lower risk of major vascular events. These findings suggest a potential benefit of statins in this population and highlight the need for confirmation through prospective randomized trials.

Data availability

Data used in this study are available upon reasonable request to corresponding author.